Krammer's post-doctoral work in the laboratory of Dr. Peter Palese at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York focused on the development of broadly neutralizing anti-hemagglutinin stalk antibodies and the design of an universal influenza virus vaccine.Krammer used a novel assay to measure the hemagglutinin stalk antibodies.Krammer and his fellow researchers have developed one of the first antibody tests in the United States for COVID-19, the disease caused by the new coronavirus.Dr. Krammer received his training in biotechnology and applied virology at the University of Natural Resources and Life Sciences in his native Austria, where he established various expression systems for antigens using insect cells/baculovirus, mammalian cells, bacteria, yeast, and plants.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Your yearly flu vaccine targets hemagglutinin, one of the two types of proteins that cover the influenza virus. Krammer used a novel assay to measure the hemagglutinin stalk antibodies. It was built from a molecule containing the stalk of the H1N1 virus—the influenza strain that was the subject of this research—and the head of an avian influenza virus that is not present in humans. The research must now be replicated with group 2 viruses to determine if hemagglutinin stalk antibodies also offer protection, research already underway in Nicaragua.
Krammer and his fellow researchers have developed one of the first antibody tests in the United States for COVID-19, the disease caused by the new coronavirus. Chembio Diagnostics Inc. of New York said it received a $4 million order from Brazil for its COVID-19 antibody test, and it plans a study of the test at several sites in the United States. Many questions remain, including how long immunity lasts to this new virus, how accurate the tests are and how testing would roll out, according to researchers and infectious disease experts.
Dr. Devi joined the faculty of Pharmacology at New York University School of Medicine and in 2002 moved to the Icahn School of Medicine at Mount Sinai as a Professor of Pharmacology and Systems Therapeutics. Fred R. Hirsch, MD, PhD, is Executive Director of the newly created Center for Thoracic Oncology at the Icahn School of Medicine at Mount Sinai, which is a multidisciplinary center focusing on development of translational and clinical science within lung cancer and mesotheliomas, including development of innovative clinical trials.